T his interview explores current controversies in the management of hypothyroidism in children.
Newborn screening programs have allowed early detection and treatment of babies with congenital hypothyroidism, but some programs do not detect cases with delayed thyroidstimulating hormone (TSH) elevation and most do not detect congenital central hypothyroidism. Lack of harmonization of TSH cut-offs means that some programs do not detect milder cases of congenital hypothyroidism. Detection of such mild cases is controversial as most patients have transient hypothyroidism and the benefit of treatment is not proven. The most common disorder of thyroid function in children is subclinical hypothyroidism-many of these cases represent TSH assay artifacts or are associated with obesity, but some will progress to overt hypothyroidism. Some patients/parents are not happy with levothyroxine treatment alone, which raises the consideration of combination thyroxine and triiodothyronine (T4 and T3) treatment. Further research, including randomized clinical trials, is required to resolve these issues.
Q. What are the limitations of current newborn screening programs for congenital hypothyroidism?
Testing for congenital hypothyroidism was added to existing newborn screening programs in the mid1970s. These programs have been incredibly successful, allowing for thyroid hormone treatment starting at a few weeks of life. 1 There are three screening test approaches to detect congenital hypothyroidism:
• Primary T4-reflex thyroid-stimulating hormone;
• Primary TSH; and
• Combination T4 and TSH.
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Q. What new techniques can improve diagnostic accuracy?
The differences in incidence rates of primary congenital hypothyroidism noted above may reflect slight differences in test cutoffs. The T4 cutoff leading to a reflex TSH test is typically <10th percentile, but in some programs it is as high as <20th percentile. As the serum TSH level surges after delivery (as high as 60-80 mU/L), and then falls over the first 5 days of life to <7 mU/L, all NBS programs have developed "age-related" TSH cutoffs, based on the age the NBS specimen is obtained. These cutoffs tend to vary from program to program. 6 Experience has shown that programs with lower TSH cutoffs tend to report a higher incidence of congenital hypothyroidism, likely the result of detection of milder cases.
Efforts toward harmonization of T4 and TSH age-related cutoffs would 
Q. What is the optimal means of management of mild subclinical hypothyroidism in children?
Mild subclinical hypothyroidism is defined by a slight serum TSH elevation, Other cases appear to be assay-dependent; repeat measurement using a different TSH assay platform may be normal. In addition, there are assay artifacts that cause falsely elevated TSH levels, including the presence of interfering heterophile antibodies (human antimouse monoclonal antibody) or macro-TSH, which is caused by a complex of TSH and an immunoglobulin.
Uncommon causes of mild TSH elevation include genetic defects resulting in an abnormal TSH beta gene, resulting in reduced TSH bioactivity, or a TSH receptor gene mutation, which causes TSH resistance.
Many children with obesity undergo testing of thyroid function and are found to have mildly elevated serum TSH levels, usually in the 5-8 mU/L range. This mild TSH elevation may represent an adaptive response to obesity, perhaps driven by elevated leptin levels, rather than true thyroid dysfunction. If these patients are able to lose weight, often the serum TSH normalizes without thyroid hormone treatment. 10 In children with a low degree of clinical suspicion of hypothyroidism, one approach is to repeat the TSH measurement in another lab using a different assay method. If serum TSH is still elevated, it may be helpful to ask the lab to check for heterophile antibodies or macro-TSH. If these steps do not resolve the problem, observation with repeat serum TSH in a few months will help determine a trend. Studies show that TSH will normalize in approximately 35% of cases, mild TSH elevation will persist in 45%, TSH will increase in 10% (but with free T4 still normal), while 10% will progress to overt hypothyroidism. 11 The most common cause of progression is autoimmune thyroid disease (Hashimoto's thyroiditis). Thus, in cases of persistent TSH elevation, it is helpful to measure anti-thyroid peroxidase and anti-thyroglobulin antibodies. For most children, levothyroxine treatment of hypothyroidism is relatively straightforward. Recommended initial L-T4 starting doses on a weight basis are well established and monitoring of serum TSH and free T4 will then allow adjustment of dosing to achieve euthyroidism. When serum TSH remains elevated despite recommended dosing, the most common explanation is a problem with adherence to daily administration of L-T4. This is particularly a concern with adolescents who are made responsible for taking their daily pill. When serum TSH remains elevated despite assurances of daily compliance, problems with levothyroxine absorption or accelerated metabolic clearance may explain persistent elevations.
Common foods in the diet or medications that are known to interfere with absorption of levothyroxine include soy protein, concentrated calcium or iron, proton pump inhibitors, and bile acid sequestrants. Common drugs that are known to increase clearance include anticonvulsants, such as phenobarbital and phenytoin and rifampin. 13 In general, levothyroxine should be taken without food.
Some parents or patients will describe persistent concerns, such as fatigue, weight gain, or behavioral or learning issues despite normalization of serum TSH and free T4. Some parents will ask for "natural" thyroid hormone rather than levothyroxine, by which they mean animal-derived desiccated thyroid preparations that contain a combination of T4 and T3.
Serum T3 levels are normalized by deiodinase activity in patients treated with levothyroxine. However, there is evidence that some patients with specific polymorphisms in genes that modulate the effects of exogenous T4, e.g. the C-allele of single nucleotide polymorphism rs22355544 in type 1 deiodinase (DI01), may not achieve serum T3 levels that are normal for them, perhaps explaining some persistent clinical features. 14 Some studies in infants with congenital hypothyroidism treated with appropriate L-T4
doses, but with persistent TSH elevation, show that adding a small dose of T3 will normalize serum TSH. 15 Recommendations regarding consideration of combination T4 and T3 use in children await further study, such as randomized clinical trials.
